Medical Data Vision, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 80%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Oct 14, 2025 4:30 pm JST Revision

3902 Medical Data Vision Co.,Ltd. 【J-GAAP】

Guidance Update Report

Medical Data Vision Co.,Ltd. <3902> [TSE Prime] announced a performance revision after the market closed on October 14th (16:30). The consolidated ordinary profit forecast for the fiscal year ending December 2025 has decreased 80.0%, from the previous forecast of 2.50 billion yen to 0.50 billion yen (compared to a loss of 0.50 billion yen in the previous period).

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (second half) consolidated ordinary profit has decreased 80.1%, from the previous forecast of 2.49 billion yen to 0.49 billion yen (compared to a loss of 0.47 billion yen in the same period of the previous year).

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2025 Prev	5,966	2,605	2,497	1,660	43.9	9	Aug 12, 2025	J-GAAP
Jul - Dec, 2025 New	3,826	495	497	280	7.4	9	Oct 14, 2025	J-GAAP
Revision Rate	-35.9%	-81.0%	-80.1%	-83.1%	-83.1%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2025 Prev	9,000	2,600	2,500	1,650	43.6	9	Feb 10, 2025	J-GAAP
Dec, 2025 New	6,860	490	500	270	7.1	9	Oct 14, 2025	J-GAAP
Revision Rate	-23.8%	-81.2%	-80.0%	-83.6%	-83.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024	3,126	-23	-477	-705	-18.5	6.50	Feb 10, 2025	J-GAAP
Jul - Dec, 2025 Guidance	3,826	495	497	280	7.4	9	Oct 14, 2025	J-GAAP
YoY	+22.4%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	6,419	1,770	1,700	979	25.6	6.50	Feb 13, 2024	J-GAAP
Dec, 2024	5,906	3	-509	-791	-20.7	6.50	Feb 10, 2025	J-GAAP
Dec, 2025 Guidance	6,860	490	500	270	7.1	9	Oct 14, 2025	J-GAAP
YoY	+16.2%	+16,233.3%	－	－	－